PLSE.NASDAQPulse Biosciences, INC
10-K/A: Pulse Biosciences Files Amendment to 10-K, Discloses Executive Changes and Compensation Details
Sentiment:
10-K/A Amendment
Pulse Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information previously omitted regarding directors, executive officers, compensation, and corporate governance.
Summary
- Pulse Biosciences filed an amendment to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The amendment includes information required by Items 10, 11, 12, 13, and 14 of Part III of Form 10-K, which were previously omitted.
- The company has included currently dated certifications required under Section 302 of The Sarbanes-Oxley Act of 2002.
- The amendment includes revisions to the cover page, including the deletion of the reference to the proxy statement.
- Paul A. LaViolette was appointed as President and Chief Executive Officer in January 2025.
- Jon Skinner was appointed as Chief Financial Officer in February 2025.
- Burke T. Barrett resigned as Chief Executive Officer in December 2024.
- The company's Board of Directors has determined that certain directors are independent within the meaning of the Nasdaq Stock Market guidelines.
- The company is not in compliance with Nasdaq listing requirement Rule 5605(c)(2)(A), which requires at least three independent directors to serve on the Audit Committee.
- The company's non-employee members of the Board have received retainer cash compensation, with each non-employee director eligible to receive an annual retainer of $55,000.
- The company completed a 2024 Rights Offering resulting in gross proceeds of $60 million.
- Robert W. Duggan, the company's majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering.
Sentiment
Score: 6
Explanation: The document is neutral in tone, primarily providing factual information about executive changes, compensation, and corporate governance. The lack of compliance with Nasdaq listing requirements and the change in CEO are slightly negative, while the completion of the rights offering is a positive.
Positives
- The company has appointed a new President and Chief Executive Officer, Paul A. LaViolette, and a new Chief Financial Officer, Jon Skinner.
- The company completed a rights offering, raising $60 million in gross proceeds.
- The company has taken steps to ensure compliance with corporate governance policies.
Negatives
- The company is not in compliance with Nasdaq listing requirement Rule 5605(c)(2)(A) regarding the Audit Committee's independence.
- The company experienced a change in CEO with Burke T. Barrett's resignation in December 2024.
Risks
- The company's forward-looking statements involve substantial risks and uncertainties.
- The company is subject to certain laws and listing requirements that mandate gender and other diversity on its board of directors, such as requirements to have a minimum number of directors from underrepresented communities, and is currently not in compliance with all of these requirements.
- The company's success depends on its ability to develop and commercialize its products.
Future Outlook
The company's future performance is subject to risks and uncertainties, and actual results may differ materially from forward-looking statements.
Industry Context
The announcement reflects ongoing executive and board adjustments common in the biotechnology industry, particularly for companies in the development and commercialization stage.
Comparison to Industry Standards
- Executive compensation packages appear competitive with industry standards for similar-sized biotechnology companies.
- The company's corporate governance structure is generally aligned with Nasdaq requirements, although there is a temporary non-compliance issue with the Audit Committee's independence.
- Rights offerings are a common financing method for development-stage biotechnology companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Burke T. Barrett | Paul A. LaViolette | January 9, 2025 | Resignation of previous CEO |
| Chief Financial Officer | N/A | Jon Skinner | February 2025 | New appointment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Audit Committee Independence | The company is not in compliance with Nasdaq listing requirement Rule 5605(c)(2)(A), which requires at least three independent directors to serve on our Audit Committee. | N/A | The Board has been evaluating ways to regain compliance with this listing requirement. |
Related Party Transactions
- Robert W. Duggan, the company's majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering.
- The company entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which we agreed to issue and sell to Mr. Duggan 10,022,937 shares of our common stock, par value $0.001 per share, in a Private Placement, at a price per share of $6.51.
Stakeholder Impact
- Shareholders: The executive changes and financial results may impact shareholder confidence and investment decisions.
- Employees: The executive changes may impact employee morale and company culture.
- Customers: The company's ability to develop and commercialize its products may impact customer access to innovative medical technologies.
Next Steps
- The company needs to regain compliance with Nasdaq listing requirement Rule 5605(c)(2)(A) regarding the Audit Committee's independence.
- The company will continue to execute its business strategy under the leadership of the new CEO.
Key Dates
| Date | Description |
|---|---|
| December 22, 2015 | 2015 Stock Incentive Plan |
| January 26, 2017 | Lease for facilities at 3955 Point Eden Way, Hayward, California |
| February 7, 2017 | Securities Purchase Agreement between Pulse Biosciences, Inc. and certain purchasers |
| May 19, 2017 | 2017 Employee Stock Purchase Plan and forms of agreements thereunder |
| November 28, 2017 | 2017 Inducement Equity Incentive Plan and forms of agreements thereunder |
| September 24, 2017 | Securities Purchase Agreement between Pulse Biosciences, Inc. and certain purchaser |
| June 18, 2018 | Plan of Conversion of Pulse Biosciences, Inc. |
| May 28, 2019 | First Amendment to the lease for facilities at 3955 Point Eden Way , Hayward, California |
| March 12, 2021 | 2017 Equity Incentive Plan and forms of agreements thereunder |
| June 30, 2021 | Securities Purchase Agreement between Pulse Biosciences, Inc. and Robert W. Duggan |
| May 27, 2022 | Indemnification Letter between Pulse Biosciences, Inc. and Robert W. Duggan |
| May 11, 2022 | Insider Trading Policy As Amended and Approved by the Board of Directors |
| September 20, 2022 | Loan Agreement between Pulse Biosciences, Inc. and Robert W. Duggan |
| January 1, 2023 | The number of shares available for issuance under the Equity Incentive Plan increased by 1,200,000 shares |
| March 17, 2023 | The Company and Mr. Duggan amended certain terms of the Loan Agreement. |
| April 30, 2023 | The Company entered into a Securities Purchase Agreement with Mr. Duggan |
| May 4, 2023 | Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc. |
| May 5, 2023 | Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc. |
| May 9, 2023 | The parties completed the Private Placement |
| June 16, 2023 | It redeemed the last of the outstanding 2022 Rights Offering Warrants at a price of $0.01 per warrant share. |
| December 19, 2023 | The number of shares available for issuance under the Equity Incentive Plan increased by 1,375,000 shares |
| March 2024 | Third Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc. |
| March 2024 | Fourth Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc. |
| April 3, 2024 | Form of Warrant |
| May 12, 2024 | Employment Agreement between Burke Barrett and the Registrant |
| June 6, 2024 | Ms. Spray ceased serving as a member of our Board of Directors and Audit Committee. |
| July 3, 2024 | We announced the closing of our 2024 Rights Offering. |
| July 15, 2024 | At-the-Market Equity Offering Sales Agreement |
| August 9, 2024 | Mr. LaViolette was elected to our board of directors |
| December 2, 2024 | The Company and Mr. Barrett agreed that he would resign from the Company |
| December 5, 2024 | Separation Agreement and Release dated December 5, 2024 Burke Barrett |
| December 6, 2024 | Mr. Barretts Separation Date |
| December 18, 2024 | Mr. Duggan and Dr. Zanganeh were married |
| January 1, 2024 | The number of shares available for issuance under the Equity Incentive Plan increased by an additional 1,200,000 shares |
| January 9, 2025 | Employment Agreement between Paul A. LaViolette and the Registrant |
| January 31, 2025 | Employment Agreement between Jon Skinner and the Registrant |
| February 4, 2025 | Employment Agreement between Jon Skinner and the Registrant |
| April 30, 2025 | Date of filing of this Amendment No. 1 to the Annual Report on Form 10-K/A |
Keywords
executive compensation, corporate governance, insider trading, rights offering, board of directors, financial reporting, Sarbanes-Oxley, Pulse Biosciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.